Literature DB >> 15935148

Regulation of ileal bile acid-binding protein expression in Caco-2 cells by ursodeoxycholic acid: role of the farnesoid X receptor.

Gabriele Campana1, Patrizia Pasini, Aldo Roda, Santi Spampinato.   

Abstract

Ursodeoxycholic acid (UDCA) is beneficial in cholestatic diseases but its molecular mechanisms of action remain to be clearly elucidated. Other bile acids, such as chenodeoxycholic (CDCA), are agonists for the nuclear farnesoid X receptor (FXR) and regulate the expression of genes relevant for bile acid and cholesterol homeostasis. In ileal cells CDCA, through the FXR, up-regulates the expression of the ileal bile acid-binding protein (IBABP), implicated in the enterohepatic circulation of bile acids. We report that UDCA (100 and 200 microM) induced a moderate increase of IBABP mRNA (approximately 10% of the effect elicited by 50 microM CDCA) in enterocyte-like Caco-2 cells and approximately halved the potent effect of CDCA (50 microM). On the contrary, UDCA reduced by 80-90% CDCA-induced IBABP transcription in hepatocarcinoma derived HepG2 cells. We confirmed that these effects on IBABP transcription required the FXR by employing a cell-based transactivation assay. Finally, in a receptor binding assay, we found that UDCA binds to FXR expressed in CHO-K1 cells (K(d)=37.7 microM). Thus, UDCA may regulate IBABP in Caco-2 cells, which express it constitutively, by acting as a partial agonist through a FXR mediated mechanism. The observation that in HepG2 cells, which do not express constitutively IBABP, UDCA was able to almost completely prevent CDCA-induced activation of IBABP promoter, suggests that tissue-specific factors, other than FXR, may be required for bile acid regulation of FXR target genes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15935148     DOI: 10.1016/j.bcp.2005.03.019

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  10 in total

Review 1.  Bile acid transporter-mediated oral drug delivery.

Authors:  Feiyang Deng; You Han Bae
Journal:  J Control Release       Date:  2020-07-22       Impact factor: 9.776

Review 2.  Intestinal Absorption of Bile Acids in Health and Disease.

Authors:  Alexander L Ticho; Pooja Malhotra; Pradeep K Dudeja; Ravinder K Gill; Waddah A Alrefai
Journal:  Compr Physiol       Date:  2019-12-18       Impact factor: 9.090

Review 3.  FXR signaling in the enterohepatic system.

Authors:  Tsutomu Matsubara; Fei Li; Frank J Gonzalez
Journal:  Mol Cell Endocrinol       Date:  2012-05-17       Impact factor: 4.102

Review 4.  FXR agonists as therapeutic agents for non-alcoholic fatty liver disease.

Authors:  Rotonya M Carr; Andrea E Reid
Journal:  Curr Atheroscler Rep       Date:  2015-04       Impact factor: 5.113

5.  Unusual binding of ursodeoxycholic acid to ileal bile acid binding protein: role in activation of FXRα.

Authors:  Changming Fang; Fabian V Filipp; Jeffrey W Smith
Journal:  J Lipid Res       Date:  2012-01-05       Impact factor: 5.922

Review 6.  Deciphering the nuclear bile acid receptor FXR paradigm.

Authors:  Salvatore Modica; Raffaella M Gadaleta; Antonio Moschetta
Journal:  Nucl Recept Signal       Date:  2010-11-19

7.  Exposure to the mycotoxin deoxynivalenol reduces the transport of conjugated bile acids by intestinal Caco-2 cells.

Authors:  Jingxuan Wang; Wouter Bakker; Weijia Zheng; Laura de Haan; Ivonne M C M Rietjens; Hans Bouwmeester
Journal:  Arch Toxicol       Date:  2022-02-28       Impact factor: 6.168

8.  Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor.

Authors:  Chia-Wen Hsu; Jinghua Zhao; Ruili Huang; Jui-Hua Hsieh; Jon Hamm; Xiaoqing Chang; Keith Houck; Menghang Xia
Journal:  Sci Rep       Date:  2014-09-26       Impact factor: 4.379

9.  Ursodeoxycholic Acid Halts Pathological Neovascularization in a Mouse Model of Oxygen-Induced Retinopathy.

Authors:  Menaka C Thounaojam; Ravirajsinh N Jadeja; Shubhra Rajpurohit; Diana R Gutsaeva; Brian K Stansfield; Pamela M Martin; Manuela Bartoli
Journal:  J Clin Med       Date:  2020-06-19       Impact factor: 4.241

Review 10.  Post-Translational Modifications of FXR; Implications for Cholestasis and Obesity-Related Disorders.

Authors:  Monique D Appelman; Suzanne W van der Veen; Saskia W C van Mil
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-27       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.